Abiopharma

New Form 8-K - Marker Therapeutics, Inc. Filed: 2025-08-26 AccNo: 0001104659-25-082783 Size: 10 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 6-K - EDAP TMS SA Filed: 2025-08-26 AccNo: 0001171843-25-005588 Size: 14 KB

Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis

General Announcement: Announcement by TMC Life Sciences Berhad - 4Q2025 and FY2025 audited results

Syndax Announces Participation in September Investor Conferences

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Voyager to Present at Upcoming Investor Conferences

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Aquestive Therapeutics to Participate in Upcoming September Investor Conferences

Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship

EyePoint Announces Participation at Upcoming Investor Conferences

Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

Unicycive Therapeutics to Participate in Upcoming Investor Events in September

Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid

Innoviva to Participate in Upcoming Investor Conferences